The War on Drugs as Economic Policy

On June 17, 1971, Richard Nixon stood before reporters and declared drug abuse “public enemy number one in the United States.” He called for a “total offensive” against drugs — funding for treatment, law enforcement, international cooperation. The War on Drugs had a name, a budget, and a theory of change: eliminate the supply of illegal drugs, raise their price, reduce demand, and the problem would shrink.

Fifty years later, the United States spends roughly $50 billion annually on drug control. It has imprisoned more people per capita than any country in the developed world, with drug offenses accounting for a significant share of that incarceration. Illicit drug use rates have not meaningfully declined compared to peer nations that spent far less on enforcement. Drug overdose deaths reached record highs in the 2020s. By its own stated metrics, the War on Drugs failed so completely and so consistently that its continued existence requires explanation beyond policy analysis. The explanation, when you look for it, is not hard to find.

The Economic Theory and Why It Was Always Wrong

The basic economic logic of drug prohibition is simple: criminalize supply, raise costs and risks for producers, reduce supply, raise prices, and consumers respond by consuming less. This is introductory microeconomics. It works for normal goods. It fails for drugs, for reasons that were knowable in 1971 and are proven beyond dispute in 2028.

The first problem is price inelasticity. Demand for addictive substances is relatively insensitive to price changes. An addict does not respond to heroin price increases the way a consumer responds to gasoline price increases — by driving less and considering a more fuel-efficient car. The addict responds by spending more money on heroin, which may mean committing more crime, selling assets, or reducing spending on food, rent, and healthcare. The demand curve for seriously addictive substances is steep in a way that elementary economics textbooks acknowledge exists but policy discussions routinely ignore.

The second problem is the black market premium. Prohibition does not eliminate markets for prohibited goods — it transfers those markets to criminal organizations that can absorb the legal risk. The criminal organization charges a premium for this risk absorption, which means prohibition increases the revenue flowing through drug markets rather than decreasing it. The Colombian cocaine trade in the 1980s generated more revenue than its country’s legal exports. Mexican drug cartels in the 2010s had annual revenues estimated in the tens of billions. Prohibition created these organizations. Legal markets do not produce Pablo Escobars.

The third problem — the most sophisticated and the most ignored — is the Alchian-Allen effect. Alchian and Allen observed in 1964 that adding a fixed cost to two substitute goods makes the higher-quality good relatively cheaper. The practical application: when transportation costs make both cheap and expensive apples more expensive, people buy the expensive ones because the relative price difference shrinks. Applied to drug markets, prohibition adds a fixed cost (risk of arrest, criminal penalty, supply chain friction) to all drugs equally. This makes more potent drugs — which deliver more effect per unit — relatively more attractive. Prohibition systematically shifts consumption toward more dangerous substances.

The Historical Evidence for the Alchian-Allen Effect in Drug Markets

The historical evidence for this effect is overwhelming and consistently ignored in policy discussions.

Alcohol prohibition in the United States (1920–1933) produced an immediate shift in consumption from beer and wine toward distilled spirits. Beer and wine are bulky relative to their alcohol content; spirits are compact and efficient. When the fixed costs of illegal distribution rose equally for all alcohol, spirits became relatively more attractive to both distributors and consumers. The temperance movement had sought to reduce alcohol consumption — it produced a shift toward harder liquor.

Drug prohibition has produced the same pattern across multiple transitions. The intensification of marijuana enforcement in the 1980s and 1990s coincided with the crack cocaine epidemic. Crack is more addictive and more dangerous than powder cocaine, but it delivers more effect per unit of transportation and legal risk. The intensification of heroin enforcement in the early 2000s contributed to the prescription opioid epidemic, as pharmaceutical companies found a legal supply chain for opioids that circumvented street-level enforcement — until opioid prescription crackdowns in the 2010s drove users to heroin, and then to fentanyl.

Fentanyl is the purest expression of Alchian-Allen logic in drug markets. It is approximately 50-100 times more potent than morphine. A kilogram of fentanyl delivers the effect of 50-100 kilograms of morphine and can be synthesized cheaply in a laboratory, making it extraordinarily valuable per unit of legal risk. Drug enforcement that focuses on weight and volume — as most enforcement does — creates maximum incentive to shift toward fentanyl. The drug overdose crisis of the 2020s is, in significant part, the Alchian-Allen effect playing out at scale. Prohibition did not produce this outcome by accident. It produced it by design, in the sense that the design creates the incentive.

The Incarceration Economics

The United States imprisoned approximately 2.3 million people in the 2010s, giving it the world’s highest incarceration rate among large countries. Drug offenses have been the single largest offense category driving federal prison populations. The annual cost of incarceration is roughly $35,000 per prisoner at the state level and higher at the federal level. Running the arithmetic on the drug enforcement incarceration produces figures in the tens of billions of dollars annually — spent on a policy that does not reduce drug use.

What does incarceration produce? A criminal justice literature that now spans decades of careful research has documented that incarceration for drug offenses produces high recidivism, employment destruction for formerly incarcerated people, community destabilization, and family breakdown. It does not produce the deterrent effect the theory predicts, because the relevant population — addicts and low-level dealers — does not respond to legal risk in the manner economic models of rational actors predict. Addiction by definition impairs rational decision-making about consequences.

The distributive effects of drug incarceration are not random. Multiple systematic studies have documented that Black Americans are arrested for drug offenses at rates several times higher than white Americans, despite roughly similar self-reported drug use rates across racial groups. This is not a coincidence of enforcement resources. It reflects where enforcement resources are directed — toward urban, poor, predominantly minority communities — and toward street-level dealing rather than wholesale distribution. The incarceration machine targets the bottom of the supply chain while the commercial infrastructure at the top operates with relative impunity.

John Ehrlichman, Nixon’s domestic policy advisor, gave an interview in 2016 that confirmed what critics had long alleged. He said the Nixon administration had two enemies: the antiwar left and Black people. “We knew we couldn’t make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin, and then criminalizing both heavily, we could disrupt those communities, we could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news.” This is not a fringe interpretation of the War on Drugs; it is a direct account from the man who helped design it.

Portugal’s Experiment and What It Tells Us

In 2001, Portugal decriminalized the personal possession of all drugs — not just cannabis, but heroin, cocaine, and methamphetamine. Possession below a threshold quantity remained a civil offense handled through “dissuasion commissions” that could recommend treatment. Drug trafficking remained criminal. The reform was accompanied by significant investment in harm reduction and treatment.

The results are well-documented. Drug-related HIV infections fell by 95% between 2001 and 2017. Drug-related deaths declined substantially and remained among the lowest in Europe. Drug use rates did not surge — they stayed roughly flat or declined for most substances among adults. The resources previously spent on prosecuting possession were redirected toward treatment and harm reduction, which produced health outcomes that enforcement never had.

Portugal’s experiment is not perfect — drug use remains a significant social problem there, and decriminalization is not legalization — but it demonstrates clearly that the predicted consequence of decriminalization (explosion in drug use) does not materialize. The feared harm reduction permissiveness turns out to be a myth. People do not begin consuming heroin in large numbers because possession is decriminalized. Most people who do not use heroin do not use it because of drug prohibition no more than most people who do not commit murder avoid murder because of homicide laws.

The Cannabis Economics

Cannabis legalization in US states beginning in 2012 provides a natural experiment in the economics of drug market normalization. The results are clear and largely in the direction reformers predicted.

Legal cannabis markets generate substantial tax revenue — Colorado, the first state to legalize recreational cannabis, generated over $1.6 billion in tax revenue in 2021. Criminal justice costs fall significantly: fewer arrests, fewer prosecutions, fewer incarcerations. Employment is created in legal retail, cultivation, and processing. The black market does not disappear immediately but shrinks as legal supply becomes more reliable and product quality more consistent.

Cannabis use rates among adults have increased modestly in legalization states, which was expected — the prior deterrent effect on casual users was real, if small. Youth use rates have not increased significantly, contrary to legalization opponents’ predictions; some studies find modest declines, consistent with the finding that regulated markets card customers where black market dealers do not. The public health apocalypse did not arrive.

What cannabis legalization demonstrates is that the economic theory underlying prohibition was always backward. Legal markets produce better outcomes than black markets on nearly every measurable dimension: product safety, price stability, tax revenue, criminal justice costs, and public health metrics. The fear that legalization would normalize and expand drug use is unsupported by evidence from states that have done it.

Why the Policy Persists

The War on Drugs has failed by its stated metrics for fifty years. It has succeeded by different metrics that were never its stated purpose. Understanding this distinction is the only way to explain why a demonstrably failed policy remains politically entrenched.

Drug prohibition has been economically productive for specific constituencies: law enforcement agencies that receive federal funding tied to drug arrests; prison industry interests whose revenue depends on incarceration volume; pharmaceutical companies whose legal opioid monopolies are protected by barriers that prohibition creates against cheaper illegal alternatives; and political coalitions that benefit from the criminalization of communities associated with the political opposition.

This is not a conspiracy theory requiring secret coordination. It is a straightforward political economy: policies persist when they serve the interests of organized, politically active constituencies, regardless of whether they achieve their stated public purposes. Drug prohibition serves identifiable interests. The diffuse public interest in better drug policy is poorly organized compared to the concentrated interests of those who benefit from the current regime.

The Conclusion

The War on Drugs is not a policy that failed to achieve its stated goals through bad luck or inadequate resources. It is a policy that was built on an economic theory that was wrong from the start, applied in ways that guaranteed the worst outcomes — more potent drugs, more criminal revenue, more incarceration without deterrence — and that persisted because it succeeded at goals it could never state publicly.

The economic evidence is not ambiguous. Price inelasticity of addiction, the Alchian-Allen effect, the black market premium, and the distributive effects of enforcement all point in the same direction: prohibition does not reduce drug use, does not reduce drug harm, and does generate enormous criminal enterprise, racially discriminatory incarceration, and fiscal waste. The countries and states that have moved toward decriminalization and harm reduction have uniformly done better on public health metrics.

What is remarkable is that this evidence has been available and largely consistent for decades, and the policy has changed only at the margins. This tells you something important about how policy actually works: it tells you that evidence is not the primary driver of policy, and that stated goals are not always the actual goals. The War on Drugs is a lesson in political economy as much as pharmacology. The policy persists because it serves someone — just not the people it claims to be protecting.